柴田 清住

Medicine & Life Sciences

1. Carcinoma 100%
2. Ovarian Epithelial Carcinoma 81%
3. Ovarian Neoplasms 75%
4. Ovary 54%
5. Survival 52%
6. Neoplasms 51%
7. leucyl-cystinyl aminopeptidase 49%
8. Endometrial Neoplasms 41%
9. Glypicans 35%
10. Dipeptidyl Peptidase 4 32%
11. Fertility 28%
12. Uterine Cervical Neoplasms 27%
13. Paclitaxel 26%
14. Angiotensin II 21%
15. Choriocarcinoma 20%
16. Cell Line 19%
17. Recurrence 19%
18. Aminopeptidases 19%
19. Endodermal Sinus Tumor 18%
20. Neprilysin 18%
21. Trophoblasts 18%
22. Indoleamine-Pyrrole 2,3,-Dioxygenase 18%
23. Neoplasm Metastasis 18%
24. Drug Therapy 18%
25. Progression-Free Survival 17%
26. Adenocarcinoma 16%
27. Clear Cell Adenocarcinoma 15%
28. Leucyl Aminopeptidase 14%
29. Lymph Node Excision 14%
30. Teratoma 14%
31. Vascular Endothelial Growth Factor A 13%
32. Cisplatin 13%
33. Matrix Metalloproteinase 9 13%
34. Carboplatin 13%
35. Endometrioid Carcinoma 13%
36. Glutamyl Aminopeptidase 13%
37. Residual Neoplasm 12%
38. Survival Rate 12%
39. Staining and Labeling 12%
40. Disease-Free Survival 11%
41. Therapeutics 10%
42. Platinum 10%
43. Spectrin 10%
44. Peptides 10%
45. In Vitro Techniques 10%
46. Active Immunotherapy 10%
47. Conditioned Culture Medium 10%
48. alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase 10%
49. Mucinous Adenocarcinoma 10%
50. Cell Proliferation 9%